{"denoms":[{"counts":[{"groupId":"BG000","value":"118"}],"units":"Participants"}],"groups":[{"description":"All patients received pasireotide LAR at 60 mg approximately once every 28 days for 6 months during the core treatment period and additional treatment cycles up to a total of 48 months during the extension phase. Patients included patients with pancreatic neuroendocrine tumors (PNETs), pituitary NETs (PiNETs), Ectopic ACTH-secreting tumor (EAS) \\& Nelson's syndrome.","id":"BG000","title":"Pasireotide LAR 60mg"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"14.56","value":"45.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"68"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"50"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"The full analysis set (FAS) consisted of all enrolled patients who received at least one dose of pasireotide LAR."}